COVID-19 boosts cannabis sales by 159%
Panic buying is no longer limited to hand sanitiser and toilet paper rolls. Reports show that anxiety-driven consumers are now stockpiling cannabis in at least four US states writes Hugo Gray.
Global markets are crumbling, lockdowns are being put into place and the worldwide death toll continues to rise thanks to the COVID-19 outbreak.
Financial anxiety is also at an all-time high, as many fear that the government-ordered shutdown of all non-essential business may have a knock-on effect on the economy and lead to significant job losses.
Although, while the unemployment rate may be climbing, the owners of cannabis dispensaries throughout North America have reported a significant upswing in business.
Outside of predictable holidays like 4:20, I'd say for sure I've not seen anything like this before. I think people pick up toilet paper and hand sanitizer and think, "That was a rough trip; I should pick up some weed". I think there is probably a fair amount [of buying] due to recreation; this isn't all due to anxiety. – Headset Director of Analytics, Liz Connors
Adult use cannabis sales in California shot up by 56% on Monday, March 16 — the same day that lawmakers set a "shelter-in-place" edict for six counties in the San Francisco Bay area—when compared to the same period during the preceding weeks, while the sale of edibles experienced a staggering 107% increase.
Preliminary data from cannabis data intelligence firm Headset has also indicated that overall legal sales spiked by 159% when compared with the same day in 2019.
"Unlike most other products in our society, especially in California, there is an extremely robust underground market for cannabis," co-founder and chairman of Harborside, Steve DeAngelo said.
"If the dispensaries in California were closed, that slack would immediately be taken up by unlicensed delivery services."
"Those unlicensed delivery services do not test their cannabis, they don't know the provenance of that cannabis, they don't know who’s been breathing on it, who's been handling it."
In San Francisco the outbreak of panic buying was initially spurred by an announcement that cannabis dispensaries would not be placed on exemption list of "essential" businesses that will be allowed to remain open during the shutdown.
However, the Department of Health would eventually elect to reverse this decision, as San Francisco residents began rushing to cannabis retailers to secure the supplies needed to ride out the quarantine.
"The Department of Health today clarified that since cannabis has medical use, dispensaries will be allowed to operate as essential businesses just like pharmacies are allowed to do," San Francisco Mayor London Breed said.
"So, it's important that we think about creative things we can do for the short term in order to get us all through this."
Reports out of Washington State have also been telling a similar story, as legal cannabis sales climbed by 23%, 14% and 33% on March 13, 14 and 15, respectively.
And just like in California, cannabis edibles received the lion's share of additional revenue thanks to a 51% boost in sales.
Conversely, the sale of flower only increased by 20%, which may be the result of hygiene concerns—as people are unlikely to share joints or bongs — during the Coronavirus pandemic.
"I think that's kind of what consumers are thinking, as well. So edible sales are really being boosted at this time," Headset Director of Analytics Liz Conners said.
"You don't have to touch your face very much to take an edible. They're all pre-wrapped, so you can hand a pre-wrapped edible to a friend."
Sales data taken from legal marijuana dispensaries in Colorado, Oregon, Alaska and Nevada have also seen similar spikes in cannabis sales.
Legislative changes are blowing through the US, and with it, an ever-increasing number of states legalising cannabis for recreational use.
With the success seen in Illinois, which legalised for adult-use on January 1 and saw products moving off the shelf at an unprecedented rate, this company is primed to take advantage of the booming US recreational market.
They have secured partnerships with the biggest cannabis companies in the US, and their portfolio is second to none.
And with the sector-wide pullback of 2019, this company is now at a bargain-basement price.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.